Ali Adili

840 total citations · 1 hit paper
29 papers, 563 citations indexed

About

Ali Adili is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ali Adili has authored 29 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Ali Adili's work include MicroRNA in disease regulation (7 papers), COVID-19 Clinical Research Studies (6 papers) and CAR-T cell therapy research (4 papers). Ali Adili is often cited by papers focused on MicroRNA in disease regulation (7 papers), COVID-19 Clinical Research Studies (6 papers) and CAR-T cell therapy research (4 papers). Ali Adili collaborates with scholars based in Iran, Iraq and Russia. Ali Adili's co-authors include Navid Shomali, Lakshmi Thangavelu, Rebar N. Mohammed, Wanich Suksatan, Supat Chupradit, Mohammed Nader Shalaby, Ahmed Raji, Ehsan Razeghian, Adel Naimi and Alexei Valerievich Yumashev and has published in prestigious journals such as Nutrition, Journal of Cellular and Molecular Medicine and Biotechnology Progress.

In The Last Decade

Ali Adili

28 papers receiving 558 citations

Hit Papers

Tumor immunotherapies by immune checkpoint inhibitors (IC... 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
    2022 306 citations Adel Naimi, Rebar N. Mohammed et al. Cell Communication and Signaling profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Adili Iran 11 260 209 164 101 86 29 563
Neşe Ünver Türkiye 10 241 0.9× 190 0.9× 254 1.5× 77 0.8× 78 0.9× 19 577
Guangdie Yang China 14 160 0.6× 170 0.8× 133 0.8× 65 0.6× 125 1.5× 20 446
Pengbo Deng China 15 210 0.8× 334 1.6× 153 0.9× 228 2.3× 214 2.5× 39 712
Yan You China 12 87 0.3× 243 1.2× 160 1.0× 61 0.6× 62 0.7× 32 512
Xiaojing An China 12 131 0.5× 195 0.9× 152 0.9× 68 0.7× 131 1.5× 29 536
Quanbao Zhang China 16 164 0.6× 252 1.2× 76 0.5× 135 1.3× 81 0.9× 40 603
Andromachi Kotsafti Italy 16 190 0.7× 211 1.0× 142 0.9× 110 1.1× 93 1.1× 38 664
Liangzhi Wen China 11 95 0.4× 300 1.4× 64 0.4× 124 1.2× 42 0.5× 26 521

Countries citing papers authored by Ali Adili

Since Specialization
Citations

This map shows the geographic impact of Ali Adili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Adili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Adili more than expected).

Fields of papers citing papers by Ali Adili

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Adili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Adili. The network helps show where Ali Adili may publish in the future.

Co-authorship network of co-authors of Ali Adili

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Adili. A scholar is included among the top collaborators of Ali Adili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Adili. Ali Adili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Adili, Ali, et al.. (2023). An updated overview of the application of CAR‐T cell therapy in neurological diseases. Biotechnology Progress. 39(5). e3356–e3356. 1 indexed citations
3.
Nazari, Ahmad, et al.. (2023). A comprehensive survey into the role of exosomes in pancreatic cancer; from the origin of cancer to the progress and possibility of diagnosis and treatment. Pathology - Research and Practice. 245. 154465–154465. 7 indexed citations
4.
Adili, Ali, et al.. (2023). A comprehensive insight into the correlation between ncRNAs and the Wnt/β-catenin signalling pathway in gastric cancer pathogenesis. Cell Communication and Signaling. 21(1). 166–166. 13 indexed citations
5.
Adili, Ali, et al.. (2022). Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives. Pathology - Research and Practice. 236. 153982–153982. 4 indexed citations
6.
Naimi, Adel, Rebar N. Mohammed, Ahmed Raji, et al.. (2022). Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling. 20(1). 44–44. 306 indexed citations breakdown →
7.
Mohammed, Rebar N., Heshu Sulaiman Rahman, Ali Adili, et al.. (2022). Correction to: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Communication and Signaling. 20(1). 90–90. 1 indexed citations
8.
Alesaeidi, ‬‬Samira, et al.. (2022). A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell International. 22(1). 269–269. 8 indexed citations
9.
Gardanova, Zhanna R., et al.. (2022). CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cellular & Molecular Biology Letters. 27(1). 35–35. 18 indexed citations
10.
Zaman, Burhan Abdullah, et al.. (2022). SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis. Pathology - Research and Practice. 239. 154131–154131. 8 indexed citations
11.
Mohammed, Rebar N., Heshu Sulaiman Rahman, Ali Adili, et al.. (2022). A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Communication and Signaling. 20(1). 79–79. 33 indexed citations
12.
Rudiansyah, Mohammad, Dmitry Olegovich Bokov, Wanich Suksatan, et al.. (2022). Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances. Journal of Cellular and Molecular Medicine. 26(15). 4137–4156. 8 indexed citations
13.
Yang, Xiaoyu, Yan Wang, Heshu Sulaiman Rahman, et al.. (2022). Expression of proliferation-related genes in BM-MSC-treated ALL cells in hypoxia condition is regulated under the influence of epigenetic factors in-vitro. Medical Oncology. 39(7). 88–88. 1 indexed citations
14.
Ebrahimzadeh, Farnoosh, Yalda Yazdani, Fatemeh Asadi, et al.. (2022). Restoration of miR-648 overcomes 5-FU-resistance through targeting ET-1 in gastric cancer cells in-vitro. Pathology - Research and Practice. 239. 154139–154139. 15 indexed citations
15.
Naghsh, Navid, et al.. (2022). A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview. Journal of Ovarian Research. 15(1). 81–81. 8 indexed citations
16.
Rahman, Heshu Sulaiman, Marwah Suliman Maashi, Svetlana Danshina, et al.. (2021). MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. Genes & Diseases. 9(4). 849–867. 25 indexed citations
17.
Motavalli, Roza, Walid Kamal Abdelbasset, Heshu Sulaiman Rahman, et al.. (2021). The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses. IUBMB Life. 73(8). 1005–1015. 11 indexed citations
18.
Pirouzpanah, Saeed, Soltanali Mahboob, Vahid Montazeri, et al.. (2019). Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: A controlled randomized clinical trial. Nutrition. 72. 110656–110656. 12 indexed citations
19.
Hajloo, Nader, et al.. (2017). The role of disease stage illness perceptions , unmet needs and fatigue in predicting quality of life in patients with cancer. 5(19). 117–132. 1 indexed citations
20.
Montazeri, Vahid, Ali Adili, Ali Jafarzadeh Esfehani, et al.. (2015). Effects of Fresh Yellow Onion Consumption on CEA, CA125 and Hepatic Enzymes in Breast Cancer Patients: A Double-Blind Randomized Controlled Clinical Trial. Asian Pacific Journal of Cancer Prevention. 16(17). 7517–7522. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neşe Ünver Breakdown of academic impact, for papers by Guangdie Yang Breakdown of academic impact, for papers by Pengbo Deng Breakdown of academic impact, for papers by Yan You Breakdown of academic impact, for papers by Xiaojing An Breakdown of academic impact, for papers by Quanbao Zhang Breakdown of academic impact, for papers by Andromachi Kotsafti Breakdown of academic impact, for papers by Liangzhi Wen
Rankless by CCL
2026